home / stock / ymab / ymab quote
Last: | $16.49 |
---|---|
Change Percent: | -0.99% |
Open: | $15.36 |
Close: | $16.49 |
High: | $17 |
Low: | $15.36 |
Volume: | 365,232 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.49 | $15.36 | $16.49 | $17 | $15.36 | 365,232 | 05-01-2024 |
$15.21 | $15.29 | $15.21 | $15.56 | $14.98 | 214,271 | 04-30-2024 |
$15.5 | $14.81 | $15.5 | $15.5686 | $14.64 | 158,043 | 04-29-2024 |
$14.71 | $14.92 | $14.71 | $15.1275 | $14.355 | 189,796 | 04-26-2024 |
$14.84 | $14.96 | $14.84 | $15.4599 | $14.28 | 365,385 | 04-25-2024 |
$15.29 | $15.33 | $15.29 | $15.4583 | $15.02 | 158,213 | 04-24-2024 |
$15.34 | $15.23 | $15.34 | $16.39 | $14.9 | 513,319 | 04-23-2024 |
$15.16 | $15.11 | $15.16 | $15.86 | $14.96 | 472,662 | 04-22-2024 |
$15.13 | $14.85 | $15.13 | $15.41 | $14.7082 | 467,188 | 04-19-2024 |
$15 | $14.93 | $15 | $15.46 | $14.8 | 410,152 | 04-18-2024 |
$15.11 | $15.14 | $15.11 | $15.41 | $14.89 | 450,829 | 04-17-2024 |
$15.14 | $14.82 | $15.14 | $15.69 | $14.495 | 442,474 | 04-16-2024 |
$14.91 | $14.37 | $14.91 | $14.95 | $14.2132 | 297,656 | 04-15-2024 |
$14.37 | $14.62 | $14.37 | $14.68 | $14.06 | 237,905 | 04-12-2024 |
$14.63 | $13.92 | $14.63 | $14.815 | $13.91 | 246,942 | 04-11-2024 |
$13.79 | $13.67 | $13.79 | $14 | $13.34 | 375,827 | 04-10-2024 |
$14.07 | $14.32 | $14.07 | $14.59 | $13.85 | 186,297 | 04-09-2024 |
$14.45 | $14.65 | $14.45 | $14.8717 | $14.02 | 168,693 | 04-08-2024 |
$14.46 | $14.58 | $14.46 | $15.08 | $14.335 | 436,698 | 04-05-2024 |
$14.56 | $14.54 | $14.56 | $14.9162 | $14.27 | 288,136 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmace...
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmace...
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmace...